Literature DB >> 35505028

In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates.

Irati Beltrán Hernández1, Timo W M De Groof2,3, Raimond Heukers2, Sabrina Oliveira4,5.   

Abstract

Photosensitizers have recently been conjugated to nanobodies for targeted photodynamic therapy (PDT) to selectively kill cancer cells. The success of this approach relies on nanobody-photosensitizer conjugates that bind specifically to their targets with very high affinities (kD in low nM range). Subsequently, upon illumination, these conjugates are very toxic and selective to cells overexpressing the target of interest (EC50 in low nM range). In this chapter, protocols are described to determine the binding affinity of the nanobody-photosensitizer conjugates and assess the toxicity and selectivity of the conjugates when performing in vitro PDT studies. In addition, and because the efficacy of PDT also depends on the (subcellular) localization of the conjugates at the time of illumination, assays are described to investigate the uptake and the intracellular degradation of the nanobody-photosensitizer conjugates.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Binding affinity; Co-cultures; Intracellular degradation; Nanobody-photosensitizer conjugate; Selective toxicity; Uptake

Mesh:

Substances:

Year:  2022        PMID: 35505028     DOI: 10.1007/978-1-0716-2099-1_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  33 in total

Review 1.  Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.

Authors:  Timo W M De Groof; Vladimir Bobkov; Raimond Heukers; Martine J Smit
Journal:  Mol Cell Endocrinol       Date:  2019-01-26       Impact factor: 4.102

Review 2.  Nanobody-based products as research and diagnostic tools.

Authors:  Thomas De Meyer; Serge Muyldermans; Ann Depicker
Journal:  Trends Biotechnol       Date:  2014-04-01       Impact factor: 19.536

3.  Nanobody-photosensitizer conjugates for targeted photodynamic therapy.

Authors:  Raimond Heukers; Paul M P van Bergen en Henegouwen; Sabrina Oliveira
Journal:  Nanomedicine       Date:  2014-01-03       Impact factor: 5.307

Review 4.  Targeting tumors with nanobodies for cancer imaging and therapy.

Authors:  Sabrina Oliveira; Raimond Heukers; Jirawas Sornkom; Robbert J Kok; Paul M P van Bergen En Henegouwen
Journal:  J Control Release       Date:  2013-09-11       Impact factor: 9.776

5.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 6.  Nanobodies and recombinant binders in cell biology.

Authors:  Jonas Helma; M Cristina Cardoso; Serge Muyldermans; Heinrich Leonhardt
Journal:  J Cell Biol       Date:  2015-06-08       Impact factor: 10.539

7.  Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.

Authors:  Timo W M De Groof; Vida Mashayekhi; Tian Shu Fan; Nick D Bergkamp; Javier Sastre Toraño; Jeffrey R van Senten; Raimond Heukers; Martine J Smit; Sabrina Oliveira
Journal:  Mol Pharm       Date:  2019-06-19       Impact factor: 4.939

8.  EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.

Authors:  Pieter B A A van Driel; Martin C Boonstra; Maxime D Slooter; Raimond Heukers; Marieke A Stammes; Thomas J A Snoeks; Henriette S de Bruijn; Paul J van Diest; Alexander L Vahrmeijer; Paul M P van Bergen En Henegouwen; Cornelis J H van de Velde; Clemens W G M Löwik; Dominic J Robinson; Sabrina Oliveira
Journal:  J Control Release       Date:  2016-03-15       Impact factor: 9.776

9.  Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging.

Authors:  Henriette S de Bruijn; Vida Mashayekhi; Tom J L Schreurs; Pieter B A A van Driel; Gustav J Strijkers; Paul J van Diest; Clemens W G M Lowik; Ann L B Seynhaeve; Timo L M Ten Hagen; Jeanine J Prompers; Paul M P van Bergen En Henegouwen; Dominic J Robinson; Sabrina Oliveira
Journal:  Theranostics       Date:  2020-01-20       Impact factor: 11.556

10.  Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.

Authors:  Marion M Deken; Marta M Kijanka; Irati Beltrán Hernández; Maxime D Slooter; Henriette S de Bruijn; Paul J van Diest; Paul M P van Bergen En Henegouwen; Clemens W G M Lowik; Dominic J Robinson; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  J Control Release       Date:  2020-04-21       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.